Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; ...
This afternoon, we released financial results for the quarter and full year ended December 31, 2025, and recent corporate updates. The press release is available on the Investors section of our ...
Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA ...
Students will be sorted into several tiers based on disability, income and other factors.
Patients taking a standard dose of CagriSema lost 20.2% of their body weight after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. “The trial did not achieve its primary endpoint of ...
Water intake can boost metabolism and control appetite to help with weight loss. Replacing high-calorie drinks with water ...
Research and Development (R&D) expenses: R&D expenses totaled $44.6 million for the fourth quarter of 2025 and $50.5 million ...
2d
The Inner Game Of Spencer Jones: Four Leadership Lessons From The Nuggets’ Newest Full-Time Player
Denver Nuggets forward Spencer Jones offers 4 leadership lessons on resilience, focus and identity that apply to executives ...
US FDA approves Sanofi and Regeneron’s Dupixent for allergic fungal rhinosinusitis: Paris Thursday, February 26, 2026, 15:00 Hrs [IST] The US Food and Drug Administration (FDA) ...
An informational overview of Ivím Health's compounded semaglutide and tirzepatide telehealth program, including GLP-1 ID cost breakdown, weekly provider check-in structure, clinical claims analysis, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results